IRIS
LOPALCO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.950
AS - Asia 4.355
EU - Europa 4.115
SA - Sud America 1.107
Continente sconosciuto - Info sul continente non disponibili 1.007
AF - Africa 204
OC - Oceania 6
Totale 22.744
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.525
SG - Singapore 1.828
IT - Italia 1.671
CN - Cina 861
BR - Brasile 852
HK - Hong Kong 484
FR - Francia 470
SE - Svezia 443
RU - Federazione Russa 435
DE - Germania 344
VN - Vietnam 307
GB - Regno Unito 227
BD - Bangladesh 203
FI - Finlandia 202
CA - Canada 164
IN - India 156
AR - Argentina 89
IQ - Iraq 75
ID - Indonesia 69
MX - Messico 69
TR - Turchia 60
ZA - Sudafrica 58
ES - Italia 51
JP - Giappone 51
CI - Costa d'Avorio 49
PK - Pakistan 45
CO - Colombia 42
EC - Ecuador 42
BE - Belgio 34
NL - Olanda 34
SA - Arabia Saudita 32
PL - Polonia 31
VE - Venezuela 31
UA - Ucraina 30
CR - Costa Rica 28
UZ - Uzbekistan 26
AT - Austria 25
TT - Trinidad e Tobago 23
MA - Marocco 22
CZ - Repubblica Ceca 21
HN - Honduras 21
PH - Filippine 21
JM - Giamaica 20
CL - Cile 19
CW - ???statistics.table.value.countryCode.CW??? 19
LT - Lituania 18
MY - Malesia 18
GT - Guatemala 17
IE - Irlanda 16
NI - Nicaragua 16
PY - Paraguay 14
PR - Porto Rico 13
SV - El Salvador 13
GP - Guadalupe 12
KE - Kenya 12
TN - Tunisia 12
NP - Nepal 11
EG - Egitto 10
IR - Iran 10
IL - Israele 9
CH - Svizzera 8
TH - Thailandia 8
AM - Armenia 7
DO - Repubblica Dominicana 7
EU - Europa 7
JO - Giordania 7
KZ - Kazakistan 7
PE - Perù 7
PT - Portogallo 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
DK - Danimarca 6
DZ - Algeria 6
ET - Etiopia 6
PA - Panama 6
QA - Qatar 6
BB - Barbados 5
HR - Croazia 5
KG - Kirghizistan 5
OM - Oman 5
SI - Slovenia 5
SN - Senegal 5
AU - Australia 4
BH - Bahrain 4
BS - Bahamas 4
LB - Libano 4
PS - Palestinian Territory 4
RS - Serbia 4
BO - Bolivia 3
CG - Congo 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
NG - Nigeria 3
RO - Romania 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
Totale 21.709
Salva come PNG Salva come JPEG
Città #
Ashburn 1.262
Fairfield 1.070
Singapore 1.003
San Jose 880
Woodbridge 694
Houston 660
Milan 580
Chandler 574
Hong Kong 477
Seattle 454
Ann Arbor 390
Cambridge 387
Nyköping 364
Wilmington 329
Beijing 326
Council Bluffs 300
Dallas 236
Los Angeles 195
Lauterbourg 186
New York 185
Rome 171
Lawrence 125
Santa Clara 121
Roxbury 120
Bari 119
Columbus 113
Munich 112
Helsinki 106
São Paulo 95
Ho Chi Minh City 92
Jacksonville 86
Buffalo 82
Des Moines 80
Boardman 79
Falkenstein 78
Nanjing 77
Moscow 67
Inglewood 65
Hanoi 60
Phoenix 60
Brooklyn 59
Princeton 58
Chicago 55
Figino 51
London 50
Abidjan 49
San Diego 46
Turku 42
Paris 39
Tokyo 39
Atlanta 38
Montreal 38
Frankfurt am Main 37
Jakarta 37
Johannesburg 36
Turin 36
Denver 35
Naples 35
Shenyang 35
Brussels 33
San Francisco 33
Toronto 33
Bar Harbor 28
Dearborn 28
Belo Horizonte 27
Baghdad 26
Brasília 26
Warsaw 26
Boston 25
Mexico City 25
Orem 25
Dong Ket 23
Manchester 23
North Bergen 23
Rio de Janeiro 23
Tashkent 22
Chennai 21
Nanchang 20
Pune 20
Poplar 19
Willemstad 19
The Dalles 18
Dhaka 17
San José 17
Jiaxing 16
Lahore 16
Managua 16
Stockholm 16
Bologna 15
Charlotte 15
Pittsburgh 15
Quito 15
Redwood City 15
Da Nang 14
Dublin 14
Florence 14
Guangzhou 14
Nuremberg 14
Salt Lake City 14
Tampa 14
Totale 14.112
Salva come PNG Salva come JPEG
Nome #
Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification 250
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 220
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 217
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 204
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 202
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 199
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 195
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 194
Basic characteristics of adults with periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome in comparison with the typical pediatric expression of disease 193
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 191
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 190
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 186
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 184
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 182
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 180
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 179
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 177
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 176
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 173
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 172
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 172
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 171
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study 164
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 163
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 161
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis 160
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 159
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 159
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 157
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study 156
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 152
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate 151
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 151
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 150
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 148
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis 147
A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study 146
Serum amyloid-A in Behçet's disease 146
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 145
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study 145
Management of Small Vessel Vasculitides 140
Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study 140
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 139
Untangling the web of systemic autoinflammatory diseases 137
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 137
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab 136
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 136
Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis 136
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 135
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 134
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 133
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 132
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 132
Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 131
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 129
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings 128
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 127
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. 126
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis 126
Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials 125
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors 125
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 125
Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art 124
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 124
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 124
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art 123
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors 121
Anakinra effectiveness in refractory polyserositis: An Italian multicenter study 120
SAT0380 FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS 119
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 118
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey 118
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis 116
IL-6 blockade in the management of non-infectious uveitis 116
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 116
improvement of refractory dysphagia in patients with idiopathic inflammatory myopathies receveing immunoglubulin intravenous therapy 114
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis 113
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry 112
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 111
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 111
Genetic and clinical features of Familial Mediterranean Fever (FMF) in a homogeneous cohort of patients from south-eastern Italy 110
Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study 110
Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series 110
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents 109
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 109
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis 109
Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for behcet's disease 109
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 109
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 107
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis 107
Complete Hydatidiform Mole Mimicking Sacroiliitis 107
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study 105
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 105
Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behḉet’s disease using explainable artificial intelligence 103
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis 103
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 102
Development and implementation of the AIDA International Registry for patients with Behçet's disease 101
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus 101
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors 98
Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis: Data From the AIDA Network Uveitis Registry 98
Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI) 97
Totale 14.085
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.129
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.129
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022810 0 0 0 0 40 82 67 53 72 81 120 295
2022/20231.547 219 199 128 123 114 241 34 198 207 12 51 21
2023/2024545 41 107 24 44 48 129 18 28 6 15 13 72
2024/20252.950 66 37 197 64 47 279 318 347 151 201 439 804
2025/20268.388 908 311 466 969 1.174 473 793 249 862 847 311 1.025
2026/20272.668 510 430 490 1.203 35 0 0 0 0 0 0 0
Totale 22.744